Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedJul 08, 2026
DataAggregated Company Financials
Companies23
  • 7D-4.6%
  • 3M-10.9%
  • 1Y10.3%
  • YTD-12.2%

Last week, the Biotech industry hasn't moved much but Hemogenyx Pharmaceuticals is up 4.8% in that time. As for the the longer term, the industry is up 16% over the past 12 months. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 08 Jul 2026UK£3.1bUK£895.1m-UK£152,946,080.9618.4x-20.6x3.5x
Fri, 05 Jun 2026UK£3.3bUK£893.0m-UK£153,080,761.2519.1x-21.7x3.7x
Sun, 03 May 2026UK£3.1bUK£888.4m-UK£109,985,069.2519.4x-27.9x3.4x
Tue, 31 Mar 2026UK£2.9bUK£893.3mUK£3.9m8.5x753.9x3.3x
Thu, 26 Feb 2026UK£3.6bUK£876.2m-UK£32,979,014.249.5x-109.5x4.1x
Sat, 24 Jan 2026UK£3.7bUK£876.0m-UK£28,730,524.3410.4x-128.9x4.2x
Mon, 22 Dec 2025UK£3.1bUK£896.9m-UK£29,260,327.7510.1x-107.6x3.5x
Wed, 19 Nov 2025UK£3.1bUK£895.4m-UK£30,539,095.9511.1x-100.2x3.4x
Fri, 17 Oct 2025UK£3.4bUK£878.7m-UK£44,547,427.2516x-75.5x3.8x
Sun, 14 Sep 2025UK£3.4bUK£857.1m-UK£84,202,253.9716.1x-40.6x4x
Tue, 12 Aug 2025UK£3.0bUK£854.6m-UK£103,140,934.7711.9x-29.2x3.5x
Thu, 10 Jul 2025UK£2.7bUK£854.3m-UK£103,572,446.5013.1x-26.1x3.2x
Sat, 07 Jun 2025UK£2.6bUK£879.7m-UK£100,553,003.0013.4x-25.7x2.9x
Mon, 05 May 2025UK£2.4bUK£879.3m-UK£68,213,282.3812.8x-35x2.7x
Wed, 02 Apr 2025UK£2.3bUK£845.7m-UK£277,344,603.8516.1x-8.3x2.7x
Fri, 28 Feb 2025UK£2.5bUK£844.4m-UK£305,826,649.8318.9x-8.3x3x
Sun, 26 Jan 2025UK£2.7bUK£842.0m-UK£295,296,216.7482.7x-9.1x3.2x
Tue, 24 Dec 2024UK£2.5bUK£841.9m-UK£294,730,607.5473.5x-8.6x3x
Thu, 21 Nov 2024UK£2.6bUK£841.0m-UK£294,350,236.6682.2x-9x3.1x
Sat, 19 Oct 2024UK£3.0bUK£840.2m-UK£295,584,370.7198.5x-10.1x3.5x
Mon, 16 Sep 2024UK£2.9bUK£832.3m-UK£311,351,926.9993.8x-9.4x3.5x
Wed, 14 Aug 2024UK£2.6bUK£838.0m-UK£257,346,669.3630.2x-10.1x3.1x
Fri, 12 Jul 2024UK£2.7bUK£835.3m-UK£260,051,093.2129.9x-10.3x3.2x
Sun, 09 Jun 2024UK£2.8bUK£836.7m-UK£279,163,323.1330.5x-9.9x3.3x
Tue, 07 May 2024UK£3.0bUK£836.4m-UK£299,218,543.5631.4x-10x3.6x
Thu, 04 Apr 2024UK£3.1bUK£903.0m-UK£202,076,785.2028.7x-15.1x3.4x
Sat, 02 Mar 2024UK£3.0bUK£897.8m-UK£203,905,345.0533x-14.9x3.4x
Mon, 29 Jan 2024UK£6.4bUK£1.3b-UK£245,297,001.0038.7x-26.3x5.1x
Wed, 27 Dec 2023UK£6.3bUK£1.3b-UK£245,330,739.0038x-25.7x5x
Fri, 24 Nov 2023UK£6.3bUK£1.3b-UK£246,160,479.0037.3x-25.4x4.9x
Sun, 22 Oct 2023UK£6.5bUK£1.3b-UK£251,206,798.0039.3x-25.9x5.1x
Tue, 19 Sep 2023UK£6.6bUK£1.3b-UK£207,484,034.0023.3x-31.6x5.1x
Thu, 17 Aug 2023UK£6.7bUK£1.3b-UK£207,822,744.0023.6x-32.1x5.3x
Sat, 15 Jul 2023UK£6.8bUK£1.3b-UK£207,342,055.0023.7x-32.8x5.4x
Price to Earnings Ratio

-32.8x


Total Market Cap: UK£6.8bTotal Earnings: -UK£207,342,055.00Total Revenue: UK£1.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Price to Earnings3Y Average -27.9x202420252026
Current Industry PE
  • Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 11% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market1.55%
Healthcare2.04%
Biotech-4.56%
Biotech-4.56%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HEMO Hemogenyx PharmaceuticalsUK£7.904.8%
+UK£2.4m		415.5%PB44.9x
COIL Coiled TherapeuticsUK£0.105.3%
+UK£2.1m		-35.5%n/a
4BB 4basebioUK£5.251.0%
+UK£776.9k		-47.5%PS48.2x
CRTX CRISM TherapeuticsUK£0.1110.3%
+UK£542.4k		-4.4%PS25.2x
AREC Arecor TherapeuticsUK£0.641.6%
+UK£377.6k		33.7%PE25.7x

Latest News

COIL
UK£0.10
Coiled Therapeutics
7D
5.3%
1Y
-35.5%
PRTC
UK£1.19
PureTech Health
7D
-13.4%
1Y
-6.9%
OXB
UK£5.98
Oxford Biomedica
7D
-4.2%
1Y
74.1%
Narrative Update • Jun 23

OXB: Fast-Track Viral Vector Services Will Support Higher Quality Business Perception

Analysts have trimmed their Oxford Biomedica price target slightly to £11.65 from £11.70, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations. What’s in the News for Oxford Biomedica Oxford Biomedica launched a new fast-track development and manufacturing service that offers an expedited route to GMP manufacture for clients using lentiviral and adeno-associated viral vectors.
APTA
UK£0.0047
Aptamer Group
7D
-5.0%
1Y
25.0%
GNS
UK£20.60
Genus
7D
-4.1%
1Y
-3.3%
Narrative Update • Jun 22

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Analysts have maintained their fair value estimate for Genus at £37.00, with recent research indicating that this figure represents a balance between differing new views from JPMorgan and BNP Paribas on the stock's prospects. Analyst Commentary Recent coverage of Genus reflects a split in opinion, with some bullish analysts highlighting upside potential while others strike a more cautious, neutral tone.
BVXP
UK£15.90
Bioventix
7D
-3.6%
1Y
-40.7%
4BB
UK£5.25
4basebio
7D
1.0%
1Y
-47.5%
HEMO
UK£7.90
Hemogenyx Pharmaceuticals
7D
4.8%
1Y
415.5%
GENF
UK£0.02
Genflow Biosciences
7D
-11.1%
1Y
166.7%
CRTX
UK£0.11
CRISM Therapeutics
7D
10.3%
1Y
-4.4%
AVCT
UK£0.70
Avacta Group
7D
-4.1%
1Y
123.8%
SCLP
UK£0.15
Scancell Holdings
7D
-15.7%
1Y
41.8%
AREC
UK£0.64
Arecor Therapeutics
7D
1.6%
1Y
33.7%
Analysis Article • May 08

Arecor Therapeutics' (LON:AREC) Performance Is Even Better Than Its Earnings Suggest

Despite posting some strong earnings, the market for Arecor Therapeutics plc's ( LON:AREC ) stock hasn't moved much...